Bayer CropScience Limited reports Q2 and H1 Results for FY 2026-27

Mumbai, November 03, 2026: Bayer CropScience Limited (BSE: 506285) announced today its unaudited results for the quarter (Q2) and half year (H1) ended September 30, 2026.

For Q2 ended September 30, 2026, Bayer CropScience Limited (BCSL) registered Revenue from Operations of ₹12,507 million as compared to ₹15,534 million in the corresponding period of FY 2025-26, a decline of 19%. Profit Before Tax stood at ₹2,114 million, compared to ₹2,003 million in the corresponding period of the previous financial year, an increase of 6%.

For the H1 ended September 30, 2026, BCSL reported Revenue from Operations of ₹30,857 million compared to ₹34,680 million for the corresponding period in FY 2025-26, a decline of 11%. Profit Before Tax for the H1 ended September 30, 2026, stood at ₹6,135 million, compared to ₹5,355 million for the corresponding period in FY 2025-26, an increase of 15%.

Commenting on the quarterly results, Simon Wiebusch, Vice Chairman & Managing Director and CEO, BCSL, said, “Q2 reflected a challenging operating environment, with an uneven monsoon affecting sowing patterns and crop protection demand, alongside lower corn acreages. Against this backdrop, we remained focused on disciplined execution, strengthening our portfolio and scaling new innovations. As Indian agriculture navigates increasing volatility, our priority is to help farmers improve productivity and resilience by bringing together innovations and partnerships across the agricultural ecosystem, while building a stronger and more sustainable business for the long term.”

Vinit Jindal, Executive Director and Chief Financial Officer, Bayer CropScience Limited, added, “Profit After Tax increased by 9% in Q2 and 13% in H1, supported by improved gross margins reflecting favourable production yields for corn seeds and cost efficiencies. Higher corn seed production volumes, combined with weaker market demand, resulted in increased inventory. Market liquidity pressures led to delayed collections and marginally higher receivables. We remain focused on disciplined working capital management and strengthening cash generation.”

The Board of Directors at its meeting held on November 03, 2026, declared an interim dividend of ₹ 90/- per equity share for the financial year ending March 31, 2027, amounting to ₹ 4,045 million.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to support efforts to master major challenges presented by a growing and aging global population and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Media Contact

Snigdha Vishal
Communications, Bayer CropScience Limited
E-mail: snigdha.vishal@bayer.com

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.